1: Ignatius Ou SH, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES. Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase- Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study. J Thorac Oncol. 2022 Sep 9:S1556-0864(22)01584-2. doi: 10.1016/j.jtho.2022.08.018. Epub ahead of print. 101(34):e30255. doi: 10.1097/MD.0000000000030255. 3: Schäkel L, Mirza S, Winzer R, Lopez V, Idris R, Al-Hroub H, Pelletier J, Sévigny J, Tolosa E, Müller CE. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy. J Immunother Cancer. 2022 Aug;10(8):e004660. doi: 10.1136/jitc-2022-004660.
合成参考文献
参考文献:10.1098/rstb.1976.0037 摘要:Glass DV. Recent and prospective trends in fertility in developed countries. Philos Trans R Soc Lond B Biol Sci. 1976 Mar 04;274(928):1–52. doi: 10.1098/rstb.1976.0037.